Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease

NCT07563491 | Completed

• 1 other identifier: Dr-Faraz-DGK
• Study Type: interventional
• Target: 824
• Locations: 1 country
• Sites: 1

Brief Summary

Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.

Conditions

Gastro Esophageal Reflux

Outcome Measures

Primary Outcomes (1)

• Sufficient relief

  The frequency of patients who achieved sufficient relief was noted.

  4 weeks

Study Arms (2)

Group-A

EXPERIMENTAL

Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.

Drug: Esomeprazole

Group-B

EXPERIMENTAL

Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.

Drug: Vonoprazan

Interventions

Esomeprazole DRUG

Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.

Group-A

Vonoprazan DRUG

Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.

Group-B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Any gender
• Aged 18 to 65 years
• Presenting with GERD

You may not qualify if:

• Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
• Any previous history of malignancy accessed from medical records.
• Pregnancy and Lactation
• Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
• History of drug allergy to proton pump Inhibitors (PPIs).

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Allama Iqbal teaching hospital

Dera Ghazi Khan, Punjab Province, 32200, Pakistan

Location

MeSH Terms

Conditions

Gastroesophageal Reflux

Interventions

Esomeprazole; 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

Condition Hierarchy (Ancestors)

Esophageal Motility Disorders; Deglutition Disorders; Esophageal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Omeprazole; 2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Faraz Ahmad

  Allama Iqbal teaching hospital Dera Ghazi Khan

  PRINCIPAL INVESTIGATOR

• Mujahid Iqbal, FCPS

  Allama Iqbal teaching hospital Dera Ghazi Khan

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Study Record Dates

• First Submitted: April 25, 2026
• First Posted: May 4, 2026
• Study Start: January 1, 2025
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: May 4, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)